Warfarin
- Generic Name
- Warfarin
- Brand Names
- Coumadin, Jantoven
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16O4
- CAS Number
- 81-81-2
- Unique Ingredient Identifier
- 5Q7ZVV76EI
- Background
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ...
- Indication
Indicated for:
1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.
2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.
3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.
...
- Associated Conditions
- Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
- Associated Therapies
- -
Rivaroxaban for Children With Giant Coronary Artery Aneurysms After Kawasaki Disease
- Conditions
- Interventions
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Children's Hospital of Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05643651
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
A Drug Interaction Study of LY3871801 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT05602675
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis
- Conditions
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Sung-Hwan Kim
- Target Recruit Count
- 240
- Registration Number
- NCT05540587
- Locations
- 🇰🇷
Bucheon St. Mary's hospital, Bucheon, Korea, Republic of
🇰🇷Yeouido St. Mary's hospital, Yeongdeungpo-gu, Seoul, Korea, Republic of
🇰🇷Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
A Study to Examine the Effect of Daridorexant on the Way the Body Absorbs, Distributes, and Gets Rid of Midazolam and Warfarin in Healthy Male Subjects
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT05480488
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 32
- Registration Number
- NCT05445232
- Locations
- 🇺🇸
Covance Dallas, Dallas, Texas, United States
🇺🇸Covance Clinical Research Unit, Daytona Beach, Florida, United States
Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 77814
- Registration Number
- NCT05438888
- Locations
- 🇯🇵
Pfizer Site, Tokyo, Japan
Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 193565
- Registration Number
- NCT05321810
- Locations
- 🇯🇵
Pfizer, Tokyo, Japan
Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05300555
- Locations
- 🇧🇷
Heart Institute - University of São Paulo, São paulo, Sao Paulo, Brazil
Apixaban in Patients With Left Ventricular Thrombus
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Saud Al Babtain Cardiac Center
- Target Recruit Count
- 50
- Registration Number
- NCT05208398
- Locations
- 🇸🇦
Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia
Treatment Patterns and Bleeding Risk of Anticoagulants in Patients With Venous Thromboembolism in Korea
- Conditions
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55759
- Registration Number
- NCT05022563
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Sungkyunkwan University, Suwon-si, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.